Aclarion, Inc. Announces Filing of Delayed 10-Q Quarterly Report
August 25, 2023 16:10 ET
|
Aclarion, Inc.
BROOMFIELD, CO, Aug. 25, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging...
Aclarion Announces Statistically Significant Nociscan® Cost-Effectiveness Abstract Presented at ISASS Annual Meeting
June 08, 2023 07:30 ET
|
Aclarion, Inc.
Nociscan cost-effectiveness abstract highlights dominance over provocative discography and can save the US healthcare system $283M to $441M annually. The International Society for the Advancement...
Aclarion’s Key Opinion Leader Program Adds Ninth Surgeon Advisor With Addition of Dean Karahalios, MD
May 23, 2023 07:30 ET
|
Aclarion, Inc.
Development of This Program Supports Aclarion’s Commitment to Lead With Strong Clinical Evidence and Engage the Payer Community Through Key Opinion Leader Advocacy Aclarion to Participate in...
Aclarion, Inc. Announces Delayed 10-Q Filing
May 23, 2023 07:00 ET
|
Aclarion, Inc.
BROOMFIELD, CO, May 23, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers...
Aclarion Announces Non-Convertible Debt Financing to Achieve Three Critical Catalysts
May 19, 2023 07:30 ET
|
Aclarion, Inc.
Up to $2M Unsecured, Non-Convertible Bridge Debt With No Required Amortization Payments Financing Supports Execution of the 2023 Plan and the Achievement of Critical Milestones in Support of...
Aclarion Appoints Nicholas Theodore, MD as Principal Investigator for CLARITY Post-Market Trial Evaluating Nociscan in the Diagnosis and Treatment of Chronic Low Back Pain
May 02, 2023 07:00 ET
|
Aclarion, Inc.
Nicholas Theodore, MD, FACS, FAANS, is Director of Neurosurgical Spine Center, Johns Hopkins, and Professor of Neurosurgery, Orthopaedics and Biomedical Engineering CLARITY is a Post-market,...
Aclarion Announces Publication of 2YR Outcomes in Groundbreaking Clinical Trial
April 24, 2023 07:00 ET
|
Aclarion, Inc.
Success rate at 2 years for discogenic low back pain surgeries was 85% for patients whose treatment strategy was consistent with Nociscan-identified discs, a 22 percentage point improvement over...
Aclarion Supports Thought Leadership at the 2nd Annual Sonntag Spine Symposium
February 15, 2023 07:00 ET
|
Aclarion, Inc.
NociscanTM is the first evidence-supported SaaS platform to objectively measure discogenic biomarkers for insight into pathological pain. Nociscan provides decision support to help bridge a...